Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

REGENT PACIFIC GROUP LIMITED
勵晶太平洋集團有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 575)

UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026

PERFORMANCE OVERVIEW

A summary of the financial performance and other notable events for the six months ended 30 June 2026 include:

- The Group recorded a profit of approximately US$544,000, which was mainly attributable to: (i) a milestone payment of US$5 million (before deduction of PRC withholding tax) due from Fosun Wanbang following NMPA approval of Senstend™ in China, offset by (ii) an impairment loss on ROU assets of approximately US$999,000; (iii) a PRC withholding tax payment of US$500,000 payable on the milestone payment mentioned above; (iv) a finance cost of approximately US$340,000 due on the shareholder's loans; and (v) the Group's operating and R&D expenses of approximately US$2.86 million.

- Fosun Wanbang received approval from the NMPA for Senstend™ on 10 June 2026, a landmark regulatory milestone for the Group. This approval triggered the milestone payment of US$5 million (before deduction of PRC withholding tax) referred to above, and a further US$2 million (before deduction of PRC withholding tax) will become payable to the Group upon first commercial sale of Senstend™ in China. The Company continues to work with Fosun Wanbang and its regulatory consultant on preparations for commercial launch, which is expected in the second half of this year.

- From a business development standpoint, Deep Longevity continued to build out its team, product, technology and commercial model, adding new customers in the US, Central Asia, Europe, Thailand and the Middle East, and progressing its Face Age clock into beta. Most notably, Deep Longevity is on track to launch its consumer digital telehealth offering in the US during the final quarter of 2026, which management believes represents a potentially transformational opportunity for the Group and a significant new source of revenue, differentiated by the independent, peer-reviewed research underpinning its BloodAge model. The scale of the opportunity is illustrated by comparable US digital telehealth platforms addressing adjacent consumer health categories, one of which was reported by The New York Times (2 April 2026) to have generated over US$400 million in revenue in its first full year of operation in 2025, and to be on track for a 2026 revenue run-rate of approximately US$1.8 billion (Forbes, 2 April 2026, citing The New York Times).

- Deep Longevity was named Runner-Up in the Nestlé VITAL Smart Aging Global Challenge, a global innovation competition that drew entries from 150 companies worldwide, with Deep Longevity's AI-powered biological ageing platform recognised among the world's top health technology innovators.

- The US Phase 3 clinical study for Fortacin™ remains on hold pending identification of a US strategic commercial partner able to fund the study.

- Recordati continues to receive uninterrupted supply of Fortacin™. Germany overtook France as the best-selling market during the first half of 2026, with total net sales for the first half of approximately €1.19 million (or approximately US$1.45 million) and generating a royalty of approximately €179,000 (or approximately US$206,000).

- In respect of other territories, commercial supply through the Group's alternative European manufacturer has now resumed, allowing other commercial partners to negotiate manufacturing and supply agreements at their own discretion. Kobayashi Pharmaceutical Co., Ltd. ("**Kobayashi**"), the Group's commercial partner for the Japanese market, continues to progress its regulatory pathway for Fortacin™ in Japan, and the Group remains in discussions with certain strategic pharmaceutical partners regarding the out-licensing of Fortacin™ to the Middle East, South America, South Africa, Canada and Mexico.

With a streamlined focus, the Company remains excited about the future prospects for the Group and the Shareholders. In China, the Company continues to support Fosun Wanbang toward the first commercial sale of Senstend™, marking a significant milestone in the Group's global commercialisation strategy.

In the US, Deep Longevity is advancing the launch of its digital telehealth offering, providing medical care online that is simple, direct, and led by licensed providers. The platform will offer medications for weight loss (such as glucagon-like peptide-1 ("**GLP-1(s)**")), peptides, women's health (such as hormone replacement therapy (HRT)) and men's health (such as testosterone therapies), with all recommendations personalised by a licensed clinician based on Deep Longevity's proprietary BloodAge report. This extends access to Deep Longevity's deep learning ageing clock technology and SenoClock® platform directly to consumers, alongside its existing work with clinics, hospitals and insurance companies.

Alongside these launches, the Group will: (i) continue to pursue the successful commercialisation of Fortacin™/Senstend™ in the remaining key markets of the US, South-East Asia, Japan, Latin America and the Middle East; (ii) continue to commercialise its deep learning ageing clock technology, partnering with clinics, laboratories and insurance companies by offering its ageing clock reports and access to its online SenoClock® software-as-a-service (SaaS) platform; and (iii) continue with its existing strategy of pursuing strategic and value-led investments in the healthcare and life sciences sectors.

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 June 2026

		(Unaudited) Six months ended 30 June	
	Notes	2026 US$'000	2025 US$'000
Revenue	4	5,275	237
Other income	4	–*	–*
Exchange (losses)/gains, net		(32)	4
Fair value (loss)/gain on FAFVPL		–*	–*
Gain on disposal of FAFVPL		–*	–
		5,243	241
Expenses:			
Employee benefit expenses		(1,788)	(1,480)
Rental and office expenses		(64)	(63)
Information and technology expenses		(82)	(75)
Marketing costs		(18)	(18)
Professional and consulting fees		(293)	(145)
Research and development expenses		(480)	(382)
Other operating expenses		(135)	(86)
Profit/(loss) from operations		2,383	(2,008)
Impairment loss on right-of-use assets	7	(999)	–
Finance costs	5	(340)	(207)
Profit/(loss) before tax		1,044	(2,215)
Income tax expense	6	(500)	–
Profit/(loss) for the period	7	544	(2,215)

* Amount is less than US$1,000

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (CONTINUED)

For the six months ended 30 June 2026

	Note	(Unaudited) Six months ended 30 June 2026 US$'000	2025 US$'000
Other comprehensive income/(expense)			
Item that may be reclassified to profit or loss:			
Exchange differences on translating foreign operations		33	(3)
Total comprehensive income/(expense) for the period		577	(2,218)
Earnings/(loss) per share	9	US cents	US cents
– Basic		0.186	(0.961)
– Diluted		0.186	(0.961)
		HK cents	HK cents
– Basic		1.453	(7.488)
– Diluted		1.453	(7.488)

* Amount is less than US$1,000

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2026

	Notes	(Unaudited) 30 June 2026 US$'000	(Audited) 31 December 2025 US$'000
ASSETS AND LIABILITIES			
Non-current assets			
Property, plant and equipment		18	15
Right-of-use assets		–	–
Intangible assets		–	–
Interest in an associate		1	1
Financial assets at fair value through other comprehensive income		–*	–*
		19	16
Current assets			
Financial assets at fair value through profit or loss		20	21
Trade receivables	10	5,218	82
Prepayments, deposits and other receivables		237	285
Restricted bank balances	12	32	32
Cash and bank balances		204	135
		5,711	555
Current liabilities			
Trade payables, contract liabilities, accruals and other payables	11	(3,925)	(3,273)
Bank borrowings		–	(4)
Shareholder's loans		(4,190)	(3,620)
Tax liabilities		(500)	–
Lease liabilities		(302)	(303)
		(8,917)	(7,200)
Net current liabilities		(3,206)	(6,645)
Total assets less current liabilities		(3,187)	(6,629)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONTINUED)

As at 30 June 2026

	Notes	(Unaudited) 30 June 2026 US$'000	(Audited) 31 December 2025 US$'000
Non-current liabilities			
Shareholder's loans		(2,060)	–
Lease liabilities		(807)	(12)
		(2,867)	(12)
NET LIABILITIES		(6,054)	(6,641)
EQUITY			
Share capital		292	292
Reserves		(6,346)	(6,933)
CAPITAL DEFICIENCY		(6,054)	(6,641)
Net liabilities value per share:			
– US cents		(2.07)	(2.28)
– HK cents		(16.23)	(17.90)

* Amount is less than US$1,000

Notes:

1. GENERAL INFORMATION

The Company was incorporated in the Cayman Islands with limited liability. The address of its registered office is P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. The address of its principal place of business is 8th Floor, Henley Building, 5 Queen's Road Central, Hong Kong. The Company's shares are listed on the Main Board of the Stock Exchange and are also traded on the Open Market (Freiverkehr) of the Frankfurt Stock Exchange.

The Company is engaged in investment holding. The principal activities of the Group consist of investments in biopharma companies and other corporate investments.

2. APPLICATION OF AMENDMENTS TO HKFRS ACCOUNTING STANDARDS

In the current interim period, the Group has applied the following amendments to HKFRS Accounting Standards issued by the Hong Kong Institute of Certified Public Accountants (the "**HKICPA**"), for the first time, which are mandatorily effective for the Group's annual periods beginning on 1 January 2026 for the preparation of the Group's condensed consolidated financial statements:

Amendments to HKFRS 9 and HKFRS 7	Amendments to the Classification and Measurement of Financial Instruments
Amendments to HKFRS 9 and HKFRS 7	Contracts Referencing Nature-dependent Electricity
Amendments to HKFRS Accounting Standards	Annual Improvements to HKFRS Accounting Standards-Volume 11

The application of the amendments to HKFRS Accounting Standards in the current interim period has had no material impact on the Group's financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

3. BASIS OF PREPARATION

The condensed consolidated financial statements have been prepared in accordance with Hong Kong Accounting Standard ("**HKAS**") 34 "Interim Financial Reporting" issued by the HKICPA and the applicable disclosures required by the Listing Rules.

As at 30 June 2026, the Group had net current liabilities and net liabilities of approximately US$3,206,000 and US$6,054,000, respectively.

These events and conditions indicate the existence of a material uncertainty which may cast significant doubt about the Group's ability to continue as a going concern and to realise its assets and discharge its liabilities in the normal course of business.

Nevertheless, the Directors had adopted the going concern basis in the preparation of these condensed consolidated financial statements of the Group, based on the measures including but not limited to the following:

(a) On 20 March 2026, Galloway has agreed to extend the repayment of the loans of US$4,190,000 for the facility dated 20 March 2025 and agreed not to demand repayment of the loans on maturity date until the Company is in a position to repay;

(b) On 26 March 2026, Galloway has granted a facility to the Company for an amount of up to US$3,000,000. The facility is unsecured, interest bearing at 12% per annum and the principal together with any interest accrued shall be repaid on the date falling eighteen months from the date of the facility letter, unless extended by mutual consent; and

(c) The Group will seek to implement operational plans to control costs and generate sufficient operating cash flows to meet its current and future obligations. These actions include cost control measures, and timely collection of outstanding receivables.

The Directors have estimated the Group's cash requirements by preparing a Group cash flow forecast for the 15 months ending 30 September 2027. The Directors are of the opinion that the Group has sufficient working capital for its present requirements, that is for 15 months ending 30 September 2027. Accordingly, the Directors are of the view that it is appropriate to adopt the going concern basis in preparing these condensed consolidated financial statements.

Notwithstanding, material uncertainty exists as to whether the Group will be able to continue as a going concern would depend upon the following:

(a) successful draw down of the facility as and when needed; and

(b) successful implementation of measures to effectively control costs and expenses and timely collection of receivables.

Should the Group fail to achieve the above-mentioned plans and measures, it might not be able to continue to operate as a going concern, and adjustments would have to be made to write down the carrying value of the Group's assets to their recoverable amounts, to provide for any further liabilities that might arise, and to reclassify non-current assets and non-current liabilities as current assets and current liabilities respectively. The effect of these adjustments has not been reflected in these condensed consolidated financial statements.

The condensed consolidated financial statements should be read in conjunction with the 2025 annual consolidated financial statements. Other than the change in accounting policies resulting from application of amendments to HKFRS Accounting Standards, the accounting policies (including the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty) and methods of computation used in the preparation of the condensed consolidated financial statements are the same as those presented in the annual consolidated financial statements for the year ended 31 December 2025.

4. REVENUE, OTHER INCOME AND SEGMENT INFORMATION

Revenue of the Group consists of milestone payment, royalty income and income generated from its IP. An analysis of the Group's revenue and other income for the period is as follows:

	(Unaudited) Six months ended 30 June	
	2026 US$'000	2025 US$'000
Milestone payment	5,000	–
Royalty income	206	149
Income generated from the IP (Deep Longevity):		
– Subscription and support service	63	87
– Provision of biological age reports	6	1
	5,275	237
Other income		
Sundry income	–*	–*
	5,275	237

* Amount is less than US$1,000

The Group identifies operating segments and prepares segment information based on the regular internal financial information reported to the CEO for his decision about resource allocation to the Group's business components and for his review of the performance of those components. The business components in the internal financial information reported to the CEO are determined following the Group's major product and service lines.

For management purpose, the Group's two product and service lines are identified as operating segments as follows:

Biopharma	:	Research, development, manufacturing, marketing and sale of pharmaceutical products and development of AI systems for the field of biological ageing clocks
Corporate Investment	:	Investment in corporate entities, both listed and unlisted

These operating segments are monitored, and strategic decisions are made based on segment operating results. There were no sales between the reportable segments.

The measurement policies the Group uses for reporting segment results under HKFRS 8 are the same as those used in its financial statements prepared under HKFRS Accounting Standards, except that finance costs are not included in arriving at the operating results of the operating segment.

Segment assets include all assets except for interest in an associate.

Segment liabilities exclude lease liabilities and shareholder's loans.

Information regarding the Group's reportable segments is set out below:

Six months ended 30 June 2026

	(Unaudited)		
	Biopharma US$'000	Corporate Investment US$'000	Total US$'000
Revenue from external customers	5,275	–	5,275
Segment profit/(loss)	4,475	(2,092)	2,383
Impairment loss on ROU asset			(999)
Finance costs			(340)
Profit before tax			1,044

As at 30 June 2026

	(Unaudited)		
	Biopharma US$'000	Corporate Investment US$'000	Total US$'000
Segment assets	5,355	374	5,729
Interest in an associate			1
Total assets			5,730
Segment liabilities	833	3,592	4,425
Shareholder's loans			6,250
Lease liabilities			1,109
Total liabilities			11,784

Six months ended 30 June 2025

	(Unaudited)		
	Biopharma US$'000	Corporate Investment US$'000	Total US$'000
Revenue from external customers	237	–	237
Segment loss	(325)	(1,683)	(2,008)
Finance costs			(207)
Loss before tax			(2,215)

As at 30 June 2025

	(Unaudited)		
	Biopharma US$'000	Corporate Investment US$'000	Total US$'000
Segment assets	353	380	733
Interest in an associate			1
Total assets			734
Segment liabilities	241	2,901	3,142
Shareholder's loans			1,240
Lease liabilities			521
Total liabilities			4,903

Disaggregation of revenue

Disaggregation of revenue from the Group's Biopharma segment and timing of revenue recognition are as follows:

	(Unaudited) Six months ended 30 June	
	2026	2025
	US$'000	US$'000
Timing of revenue recognition		
At a point in time		
Milestone payment	5,000	–
Royalty income	206	149
Provision of biological age reports	6	1
	5,212	150
Over time		
Subscription and support service	63	87
	5,275	237
By geographical location of external customers		
Europe	221	169
US	4	4
Middle East	15	8
Asia Pacific	5,035	56
	5,275	237

The geographical location of revenue from external customers is based on the location of customers of the Group's Biopharma segment.

Information about major customers

Revenue from customers of the Group's Biopharma segment contributed to 10% or more of the Group's total revenue is as follows:

	(Unaudited) Six months ended 30 June	
	2026	2025
	US$'000	US$'000
Customer A	206*	149
Customer B	–*	15
Customer C	5,000	–

* Amount is less than 10% of the Group's total revenue

5. FINANCE COSTS

	(Unaudited) Six months ended 30 June	
	2026	2025
	US$'000	US$'000
Interest expenses on shareholder's loans	279	174
Interest expense on lease liabilities	61	33
	340	207

6. INCOME TAX EXPENSE

No provision for Hong Kong Profits Tax has been made as the relevant group entities did not have assessable profits subject to Hong Kong Profits Tax for the six months ended 30 June 2026 (six months ended 30 June 2025: nil).

A withholding tax payment of US$500,000 was recorded in respect of a milestone payment of US$5 million due from Fosun Wanbang in the PRC for the six months ended 30 June 2026 (six months ended 30 June 2025: nil).

Tax charge on profits assessable elsewhere have been calculated at the rates of tax prevailing in the countries in which the Group operates, based on existing legislation, interpretation and practices in respect thereof.

7. PROFIT/(LOSS) FOR THE PERIOD

	(Unaudited) Six months ended 30 June	
	2026 US$'000	2025 US$'000
Profit/(loss) for the period is arrived at after charging/(crediting):		
Auditors' remuneration		
– audit services	–	–
– other services	19	19
Depreciation of:		
– property, plant and equipment	4	4
Impairment loss on ROU assets**	999	–
Short-term lease expenses	8	8
Low-value assets lease expenses	2	2
Fair value (loss)/gain on FAFVPL	–*	–*
Gain on disposal of FAFVPL	–*	–
Exchange losses/(gains), net	32	(4)

* Amount is less than US$1,000

** During the period, management reviewed the recoverable amount of the Group's ROU assets by reference to its results and cash flow forecasts covering the full lease term. This review resulted in the recognition of an impairment loss of approximately US$999,000.

8. DIVIDENDS

No interim dividend has been declared or paid in respect of the six months ended 30 June 2026 (six months ended 30 June 2025: nil).

9. EARNINGS/(LOSS) PER SHARE

The calculation of basic earnings/(loss) per share is based on the profit/(loss) for the period and the weighted average number of ordinary shares in issue during the period.

	(Unaudited) Six months ended 30 June	
	2026 US$'000	2025 US$'000
Profit/(loss) for the period	544	(2,215)
Weighted average number of ordinary shares in issue (note)	291,815,782	230,539,519
Basic earnings/(loss) per share (US cents)	0.186	(0.961)

The computation of diluted earnings/(loss) per share does not assume the exercise of the Company's share options because the exercise price of those options was higher than the average market price of the Shares for the six months ended 30 June 2026 and 2025. Accordingly, the diluted earnings/(loss) per share is the same as the basic earnings/(loss) per share.

10. TRADE RECEIVABLES

The ageing analysis of trade receivables, based on the date of invoice, is as follows:

	(Unaudited) 30 June 2026 US$'000	(Audited) 31 December 2025 US$'000
Within 1 month	5,218	82

The Group applies credit policies appropriate to the particular business circumstances concerned and generally requires outstanding amounts to be paid within 20 to 45 days (31 December 2025: 20 to 45 days) of invoice date.

11. TRADE PAYABLES, CONTRACT LIABILITIES, ACCRUALS AND OTHER PAYABLES

	(Unaudited) 30 June 2026 US$'000	(Audited) 31 December 2025 US$'000
Trade payables	14	17
Contract liabilities	103	26
Accruals and other payables	3,808	3,230
	3,925	3,273

The ageing analysis of the trade payables, based on the date of invoice, is as follows:

	(Unaudited) 30 June 2026 US$'000	(Audited) 31 December 2025 US$'000
Within 1 month or on demand	12	15
After 1 month but within 3 months	–	2
After 3 months but within 6 months	2	–
	14	17

12. CHARGE ON ASSETS

As at 30 June 2026, a bank deposit amounting to US$32,000 (31 December 2025: US$32,000) is a deposit held by the bank as security for the corporate credit cards provided to a subsidiary of the Company.

TRADING RECORD OVER LAST FIVE YEARS

	Six months ended 30 June	Year ended 31 December				
	2026	2025	2024	2023	2022	2021
	US$'000	US$'000	US$'000	US$'000	US$'000	US$'000
Total revenue and fair value gain/(loss) on financial instruments	5,243	348	656	539	(4,020)	18,235
Revenue less expenses before impairment losses and provision	2,383	(4,312)	(4,337)	(27,713)	(34,995)	(13,873)
Impairment losses	(999)	(30)	–	(2,670)	–	–
Operating profit/(loss) after impairment losses and provision	1,384	(4,342)	(4,337)	(30,383)	(34,995)	(13,873)
Finance costs	(340)	(368)	(171)	(80)	(1,013)	(1,218)
Profit/(loss) before tax	1,044	(4,710)	(4,508)	(30,463)	(36,008)	(15,091)
Income tax (expense)/credit	(500)	–	26	5,414	(419)	2,493
Profit/(loss) for the period/year	544	(4,710)	(4,482)	(25,049)	(36,427)	(12,598)

MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE GROUP'S PERFORMANCE

REVENUE AND PROFIT

The Group recorded a profit of approximately US$544,000 for the six months ended 30 June 2026 compared to the loss of approximately US$2.22 million for the six months ended 30 June 2025.

The main elements of the profit/(loss) are analysed as follows:

	Notes	Six months ended 30 June 2026 US$'000	Six months ended 30 June 2025 US$'000	Increase/ (decrease) %
Revenue	(i)	5,275	237	2,126
Other income		–*	–*	–
Exchange (losses)/gains, net		(32)	4	NA
Fair value (loss)/gain on financial instruments		–*	–*	NA
R&D expenditures	(ii)	(480)	(382)	26
G&A expenditures	(iii)	(2,380)	(1,867)	27
Impairment loss on ROU assets	(iv)	(999)	–	NA
Finance costs	(v)	(340)	(207)	64
Income tax expense	(vi)	(500)	–	NA
Profit/(loss) for the period		544	(2,215)	NA

* Amount is less than US$1,000

(i) The Group recorded a milestone payment of US$5 million (before deduction of PRC withholding tax) due from Fosun Wanbang following NMPA approval of Senstend™ received on 10 June 2026 in the PRC, for the six months ended 30 June 2026 (six months ended 30 June 2025: nil).

(ii) The Group recorded R&D expenditures of approximately US$480,000 for the six months ended 30 June 2026 as compared to approximately US$382,000 for the corresponding period in 2025. The increase was mainly due to an increase in personnel cost.

(iii) The Group recorded G&A expenditure of approximately US$2,380,000 for the six months ended 30 June 2026 as compared to approximately US$1,867,000 for the corresponding period in 2025. The increase was mainly due to an increase in personnel cost and professional and consulting fee.

(iv) The Group recorded an impairment loss on ROU assets of approximately US$999,000 for the six months ended 30 June 2026, as the recoverable amount of its ROU assets has been determined to be nil by reference to a 36-month Group cash flow forecast (six months ended 30 June 2025: nil).

(v) The Group recorded finance costs of approximately US$340,000 for the six months ended 30 June 2026 as compared to approximately US$207,000 for the corresponding period in 2025, as a result of an increase in the weighted average amount of the outstanding shareholder's loans of approximately US$4.66 million for the six months ended 30 June 2026 compared to approximately US$3.55 million for the corresponding period in 2025.

(vi) The Group recorded a tax payment of US$500,000 for the six months ended 30 June 2026, representing PRC withholding tax on the milestone payment of US$5 million due from Fosun Wanbang (six months ended 30 June 2025: nil).

FINANCIAL POSITION

Capital deficiency decreased to approximately US$6.05 million as at 30 June 2026 from approximately US$6.64 million as at 31 December 2025. The decrease was mainly due to the profit of approximately US$544,000 recorded for the six months ended 30 June 2026.

The Group's assets also comprised: (i) cash and bank balances of approximately US$204,000; (ii) property, plant and equipment and prepayments, deposits and other receivables of approximately US$255,000; (iii) restricted bank balances of US$32,000; (iv) trade receivables of approximately US$5.22 million; and (v) listed and unlisted investments of approximately US$20,000.

The Group's liabilities comprised: (i) trade payables, contract liabilities, accruals and other payables of approximately US$3.93 million; (ii) long-term and short-term lease liabilities of approximately US$1.11 million; (iii) long-term and short-term shareholder's loans of US$6.25 million; and (iv) tax liability of US$500,000.

PLETHORA'S FINANCIAL RESULTS

Plethora recorded an operating profit of approximately £3.23 million (or approximately US$4.33 million) for the six months ended 30 June 2026, as compared to an operating loss of approximately £79,000 (or approximately US$102,000) for the corresponding period in 2025.

The operating profit of Plethora for the six months ended 30 June 2026 mainly reflected: (i) a milestone payment of approximately £3.73 million (or US$5 million) due from Fosun Wanbang (six months ended 30 June 2025: nil); and (ii) royalty income of approximately £153,000 (or approximately US$206,000) due from Recordati (six months ended 30 June 2025: approximately £115,000 (or approximately US$149,000)); offset by (iii) R&D costs relating to the regulatory and Phase 3 clinical study for the FDA approval process of Fortacin™ in the US of approximately £78,000 (or approximately US$104,000) (six months ended 30 June 2025: approximately £70,000 (or approximately US$91,000)); and (iv) G&A expenses of approximately £201,000 (or approximately US$270,000) (six months ended 30 June 2025: approximately £124,000 (or approximately US$161,000)).

As at 30 June 2026, Plethora had cash resources of approximately £12,000 (or approximately US$16,000) (31 December 2025: approximately £14,000 (or approximately US$19,000)), with ongoing financial support being provided by the Group.

Development Plan for Senstend™ in the PRC

Fosun Wanbang received approval from the NMPA for Senstend™ on 10 June 2026, a transformational regulatory milestone for the Group. This approval triggered a payment of US$5 million (before deduction of PRC withholding tax) to the Group due from Fosun Wanbang. A further US$2 million (before deduction of PRC withholding tax) will become payable to the Group upon first commercial sale of Senstend™ in China. The Company continues to work with Fosun Wanbang and its regulatory consultant on the preparations for commercial launch and the subsequent commercialisation process, which is expected during the second half of this year.

Development Plan for Fortacin™ in the US

The US Phase 3 clinical study for Fortacin™ remains on hold pending identification of a US strategic commercial partner able to fund the study. These studies are currently estimated to begin in the second half of 2027, subject to funding being secured.

Based on a quotation from the shortlisted clinical research organisation ("**CRO**"), the estimated total project budget for the Phase 3 clinical study (covering the randomised controlled trial (RCT), reference listed drug (RLD) and combination rule studies, across 25 study sites in the US with 180 subjects enrolled) is approximately US$10 million, comprising CRO services, technology licensing and hosting fees for the electronic data capture platform, and pass-through fees to sites.

Commercialisation of Fortacin™ in Europe by Recordati

Recordati continues to receive uninterrupted supply of Fortacin™. A summary of Recordati's sales for the six months ended 30 June 2026 shows total net sales of approximately €1.19 million (or approximately US$1.45 million) and generating a royalty of approximately €179,000 (or approximately US$206,000), with Germany overtaking France as the best-selling market during the period.

Commercialisation of Fortacin™ in other countries

Kobayashi entered into a licence agreement with the Company for the commercialisation of Fortacin™ in Japan on 26 July 2024. Kobayashi is progressing discussions with the Japanese health authority to determine whether a Phase 3 clinical study will be required.

The Group is also in discussions with certain commercial strategic pharmaceutical partners regarding the out-licensing of Fortacin™ to certain territories, including the Middle East, South America, South Africa, Canada and Mexico. The Group will continue to work with its current and prospective commercial partners and will update Shareholders on material developments as they occur.

DEEP LONGEVITY

Deep Longevity continued to build out its team, product, technology and commercial model during the six months ended 30 June 2026. Deep Longevity is focused on commercialising a suite of AI-driven biological ageing clocks, and its priority for 2026 remains scaling in the US market via the launch of its consumer digital telehealth offering.

The longevity sector is transitioning from an emerging trend to a more established category. As is typical in a maturing market, some early entrants are consolidating while stronger players gain momentum.

Customer Adoption

Deep Longevity re-signed Sheba Medical Centre for the six months ended 30 June 2026 and onboarded Referans Clinical Laboratory and Polyclinic Center LLC ("**Referans Clinical**"), a private medical group in Azerbaijan. Two further customers, LongevityDoc GmbH ("**LongevityDoc**") and Convenience Hospital Company Limited, were added in April and May 2026 respectively.

Beyond the US, Deep Longevity added new customers in Central Asia, Europe, Thailand and the Middle East for the six months ended 30 June 2026. Adoption in Central Asia – a new market for Deep Longevity – has been particularly encouraging, and usage in Thailand is also increasing significantly.

Business Development

In the US, Deep Longevity is seeing increasing interest from employers and telehealth providers, reflecting a broader shift toward integrating biological age metrics into health and wellness programmes; management's focus is on converting this interest into sustained revenue. Deep Longevity's active pipeline spans the US, Europe, Asia and South America, including several large enterprise discussions.

In a further endorsement of its technology, Deep Longevity was named Runner-Up in the Nestlé VITAL Smart Aging Global Challenge, a global innovation competition that drew entries from 150 companies worldwide, having been selected by Nestlé's expert panel for its ability to deliver real-time, validated biological age measurements that help consumers understand and act on their health. This recognition reflects Deep Longevity's growing global footprint, which now spans partnerships with organisations including Humansa VD Limited in Hong Kong, Referans Clinical in Azerbaijan, Chularat Hospital in Thailand and LongevityDoc in Europe.

Deep Longevity has evaluated a consumer digital telehealth offering focused on longevity and biological ageing for the US direct-to-consumer ("**D2C**") market, positioned alongside comparable platforms such as Hims & Hers Health, Inc. (https://www.hims.com/sexual-health), Roman Health Ventures Inc. (https://ro.co), MEDVi, LLC ("**MEDVi**") (https://home.medvi.org/#womens-health), Modern Metabolic Medicine, Inc (through JoinEm) (https://joinem.co) and Willow Health Services, Inc. (https://www.startwillow.com). Management expects to launch the D2C digital telehealth offering in the US during the final quarter of this year, a development the Board regards as potentially transformational for the Group, with the opportunity to become a significant new source of revenue alongside Deep Longevity's existing business-to-business ("**B2B**") model.

The scale of revenue achievable by consumer digital telehealth platforms addressing adjacent health and wellness categories has been well documented: MEDVi, a US digital telehealth platform focused on GLP-1 weight-loss and related therapies, was reported by The New York Times (2 April 2026) to have generated over US$400 million in revenue in 2025, its first full year of operation, and to be on track for a 2026 revenue run-rate of approximately US$1.8 billion (Forbes, 2 April 2026, citing The New York Times). Deep Longevity's proposed offering will be similar to MEDVi's in respect of product category, spanning compounded GLP-1s, hormone replacement therapy, testosterone optimisation and peptide products, though no assurance can be given that Deep Longevity will achieve comparable results; management nonetheless believes this illustrates the scale of consumer demand and revenue potential in the US digital telehealth market that Deep Longevity's offering is intended to address. Management further believes this offering could be differentiated through the independent, peer-reviewed clinical research underpinning Deep Longevity's technology: Deep Longevity's BloodAge model was the subject of a peer-reviewed study by Goshen et al. (Aging and Disease, 2026), which followed approximately 2,600 adults over an average of 9.2 years and found that each additional year of gap between biological and chronological age was independently associated with a 15% increase in mortality risk and a 6% increase in hospitalisation risk, after adjusting for age, sex, Body Mass Index (BMI), smoking and hypertension.

The proposed offering would use a routine blood test to indicate whether a consumer is a "faster ager" – someone whose biological age is advancing more quickly than their chronological age – via an AI-generated BloodAge report. It would be structured as a digital telehealth service offering doctor-guided access to compounded GLP-1 weight-loss therapies, hormone replacement therapy, testosterone optimisation and peptide products, among other categories, broadly following the physician consultation, prescription and ongoing monitoring model used by comparable platforms, but anchoring the initial treatment plan and subsequent adjustments to the user's BloodAge report rather than to self-reported symptoms or a single biomarker. A beta version of the offering, branded Accrua, is now live for internal testing ahead of the planned final quarter of 2026 US launch.

Management expects this model to be capital-efficient to build, relying on a network of independent, licensed physicians and pharmacy or compounding partners for clinical delivery rather than requiring Deep Longevity to own clinical infrastructure or carry drug inventory directly, and views the offering as a potential source of largely subscription-based revenue relative to the capital required to launch it. The commercial structure, brand positioning, regulatory considerations and specific partnership approach remain under evaluation, including ensuring that consumer-facing claims accurately reflect what the published research supports for the BloodAge model, as distinct from clinical or regulatory validation of the consumer product itself.

Deep Longevity is also in the process of launching a new product, Face Age, and has begun to attract interest from the beauty, cosmetics and wellness segments.

Research and Development

The Face Age clock – which uses AI-based facial image analysis to assess biological ageing and identify visible indicators related to skin health and appearance – has entered beta, an important product milestone. The Blood Age clock continues to be enhanced, with ongoing improvements to both the algorithm and data-parsing capabilities, and a redesigned Blood Age report is in development for launch in the third quarter of 2026.

Marketing, PR and Technology

Targeted marketing campaigns and Deep Longevity's upgraded website continue to generate a steady flow of inbound interest, supporting conversations across multiple geographies and customer segments. Deep Longevity is attending B2B events in the US, Europe and Asia to build its pipeline.

Deep Longevity is actively working toward the Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliance as part of its strategy to deepen its presence in the US healthcare ecosystem – a critical step in enabling partnerships with telehealth providers, employers and clinical organisations. All ageing clocks are being integrated with the SenoClock® platform on an ongoing basis, alongside continued improvements to infrastructure and reporting systems to support a growing global customer base.

Financials

For the six months ended 30 June 2026, Deep Longevity recognised revenue of approximately US$69,000, with a further approximately US$103,000 of revenue pending recognition across existing customer contracts as at 30 June 2026.

OUTLOOK

We are optimistic about the prospects for our businesses going into the second half of 2026. Following Fosun Wanbang's receipt of the NMPA approval for Senstend™ on 10 June 2026 – which we regard as transformational for the Group – our priorities for the second half of the year are to: (i) support Fosun Wanbang's preparations for the first commercial sale of Senstend™ in China, which will trigger a further milestone payment of US$2 million (before deduction of PRC withholding tax) to the Group; (ii) secure a US strategic commercial partner to fund the Phase 3 clinical study for Fortacin™ in the US; (iii) support Kobayashi in its regulatory pathway for Fortacin™ in Japan, and progress our discussions with strategic commercial pharmaceutical partners regarding the out-licensing of Fortacin™ to the Middle East, South America, South Africa, Canada and Mexico; and (iv) continue to scale Deep Longevity's commercial model in the US and other markets, including the planned final quarter of 2026 launch of our consumer digital telehealth offering, which we believe has the potential to be transformational for the Group and a significant driver of future revenue, and the launch of the Face Age clock.

We continue to believe Deep Longevity is well positioned as a leader in its sector – AI-led machine learning to determine biological age via its SenoClock® SaaS platform – supported by the growing recognition of its technology, including its recent Runner-Up recognition in the Nestlé VITAL Smart Aging Global Challenge and independent, peer-reviewed research supporting its BloodAge model.

With a streamlined focus, the Company remains optimistic about the future prospects for the Group despite ongoing global uncertainty and remains committed to driving the business forward across its key operating divisions.

The Company wishes to thank our Shareholders for their continued support and our employees for their hard work during another challenging but rewarding first half of the year.

STRATEGIC PLAN

The Board and the Company's senior management play an active role in the Company's strategy development and planning process. The CEO regularly interacts with the Board in respect of the strategic plan and direction of the Company, during which an agreed approach for the Company to generate and preserve its long-term value was determined, while agreeing shorter-term priorities and objectives. In addition, the risks associated with the current operations and strategy of the Company are currently being tested by way of an internal audit process conducted through an independent service provider, with the aim of identifying ways in which the Company can better identify and manage its risks.

In order to generate or preserve value over the longer term, the Group is committed to:

- the divestment of non-core assets and investments to enable the Company to pursue growth and opportunistic investments in the life sciences sector;
- utilising international and local expertise to tackle difficult markets, deliver results and achieve global recognition; and
- employing the Company's Hong Kong listing through strong liquidity and access to international capital markets, together with maintaining our corporate governance and social responsibility standards in line with the policies set down by the Stock Exchange and best practice.

The Company is committed to creating Shareholder value and returns through accretive acquisitions and returning surplus capital to Shareholders by way of an effective dividend policy and share repurchase programme.

FUNDING

As at 30 June 2026, the Group had approximately US$204,000 in cash.

GEARING RATIO

Due to the capital deficiency position as at 30 June 2026, the gearing ratio calculated as a percentage of the Group's long-term debts over total equity became a meaningless figure (31 December 2025: meaningless figure).

CONTINGENT LIABILITIES

The Group had no material contingent liabilities as at 30 June 2026 (31 December 2025: nil).

SIGNIFICANT INVESTMENTS

As at 30 June 2026, the Group did not have any significant investment in equity interest in any other companies and did not own any properties (31 December 2025: nil).

MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES

The Group did not have any material acquisitions or disposals of subsidiaries during the six months ended 30 June 2026 (six months ended 30 June 2025: nil).

MATERIAL CHANGES FOR THE INTERIM PERIOD

Trade receivables increased by approximately 6,263% to approximately US$5.22 million as at 30 June 2026 from US$82,000 as at 31 December 2025. The increase was mainly due to the milestone payment of US$5 million (before deduction of PRC withholding tax) due from Fosun Wanbang as at 30 June 2026 (31 December 2025: nil).

Saved as disclosed in this announcement, there were no significant changes in the Group's financial position and from the information disclosed under "Management's Discussion and Analysis of the Group's Performance" of this announcement.

CHARGE ON ASSETS

As at 30 June 2026, a bank deposit amounting to US$32,000 is a deposit held by the bank as security for the corporate cards provided to a subsidiary of the Company (31 December 2025: US$32,000).

MANAGEMENT OF RISK

The most significant risks affecting the profitability and viability in respect of the Group are the Group's interest in Plethora and Deep Longevity.

EVENTS AFTER REPORTING DATE

There are no material events after the reporting date.

EMPLOYEES AND REMUNERATION

The Group, including subsidiaries but excluding an associate, employed 15 employees and 2 consultants as at 30 June 2026 (30 June 2025: 17 employees and 1 consultant). The remuneration policy is to reward key employees by a combination of salaries, profit related discretionary bonuses, share options and share awards, where appropriate. For employees below Board level, remuneration is determined by the Director(s) responsible for the division whilst, for NEDs (including INEDs), remuneration is recommended by the Remuneration Committee and approved by the Board. For individual ED and senior management, the Remuneration Committee determines, with delegated responsibility, their remuneration packages. In all cases, profit related discretionary bonuses, grants of share options and share awards will be agreed by the Remuneration Committee.

The Company recognises that employees are one of the Group's most important assets. The Company offers rewards or other incentives to motivate the personal growth and career development of employees. During the six months ended 30 June 2026, the Share Option Scheme (2016), which was adopted by the Company on 10 June 2016, expired on 9 June 2026; and a restricted share unit scheme (the "**RSU Scheme**") was adopted by the Company upon the Shareholders approval at the annual general meeting of the Company held on 29 May 2026, with the grant of listing status of the awarded shares under the RSU Scheme by the Listing Committee of the Stock Exchange on 1 June 2026. Going forward, the RSU Scheme will replace the Share Option Scheme (2016) as a method for providing equity incentivisation for the Group's directors and employees. Further details are set out in the Company's announcements dated 4 May 2026 and 29 May 2026, and circular dated 7 May 2026 respectively and will be presented in the 2026 Interim Report.

INTERIM DIVIDEND

The Directors have resolved not to declare an interim dividend in respect of the six months ended 30 June 2026 (six months ended 30 June 2025: nil).

CORPORATE GOVERNANCE

The Company is committed to maintaining high standards of corporate governance in accordance with the CG Code and believes that strong governance practices are fundamental to maintaining investor confidence and ensuring the sustainable development of the Company. The Board is responsible for performing the corporate governance functions as set out under Code Provision A.2.1 of the CG Code.

During the six months ended 30 June 2026, the Company has complied with the Code Provisions set out in the CG Code. The corporate governance policy and practices adopted during the six months ended 30 June 2026 remained in line with those in place for the financial year ended 31 December 2025 as disclosed in the corporate governance report of the 2025 Annual Report.

As at 30 June 2026 and as of the date of this announcement, the Board had six Directors, including one ED (being the CEO), two NEDs and three INEDs. The Chairman (who is a NED) leads and is responsible for running the Board. The CEO leads the management team and is responsible for running business and daily operations of the Company. The two roles are separate and performed by different individuals. In the course of overseeing management and business performance, the Board is assisted by the Audit Committee, the Remuneration Committee and the Nomination Committee, with each operating under written terms of reference as approved and reviewed from time to time by the Board. There are also an Investment Committee and an Inside Information Committee under the authority of the Board to oversee various matters, including but not limited to compliance and disclosure.

THE CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS AND RELEVANT EMPLOYEES

The Company has adopted its own Securities Dealing Code regarding securities transactions by Directors and relevant employees on terms no less exacting than the required standards set out in the Model Code. Reminders are sent to the Directors and relevant employees that they should comply with the restriction on dealing of the securities of the Company during the blackout periods as specified in the Securities Dealing Code. The Securities Dealing Code is available on the Company’s website.

Having made specific enquiries with the Directors, the Company confirmed that all Directors have complied with the required standards set out in the Securities Dealing Code and the Model Code during the six months ended 30 June 2026.

REVIEW OF UNAUDITED FINANCIAL INFORMATION

The unaudited consolidated financial information of the Group for the six months ended 30 June 2026 as set out in this announcement has been reviewed by the Audit Committee. The Directors acknowledge their responsibility for preparing the accounts and presenting a balanced, clear and comprehensive assessment of the Group's performance, position and prospects. An explanation of the basis on which the Company generates or preserves value over the longer term (the business model) and the strategy for delivering the Company's objectives are set out in the paragraph headed "Strategic Plan" in the "Management's Discussion and Analysis of the Group's Performance" in this announcement.

AUDITOR

Reference is made to the announcement of the Company in relation to the change of Auditor dated 21 June 2023. The Board had conducted an external audit tender process in accordance with good corporate governance practice as BDO Limited ("**BDO**"), the resigning Auditor, has provided auditing services to the Company for 12 financial years. As a result of this process, the Company announced that BDO had resigned as the Auditor with effect from 21 June 2023 and RSM Hong Kong ("**RSM**") had been appointed as the Auditor with effect from 21 June 2023. BDO had confirmed in its resignation letter to the Company and the Audit Committee that there were no matters in respect of its resignation that needed to be brought to the attention of the holders of securities of the Company.

The Board, with the recommendation of the Audit Committee, had resolved to appoint RSM with effect from 21 June 2023 as the new Auditor to fill the casual vacancy following the resignation of BDO, and to hold office until the conclusion of the next annual general meeting of the Company subject to appointment by the Shareholders in accordance with the articles of association of the Company by way of ordinary resolution. The ordinary resolution to re-appoint RSM as the Auditor had been passed by the Shareholders at the annual general meeting of the Company held on 30 May 2024.

Reference is also made to the announcement of the Company in relation to the change of Auditor dated 16 July 2024. The Company announced that RSM had resigned as the external Auditor with effect from 16 July 2024 as the Board and RSM could not reach a consensus on the audit fee for the financial year ended 31 December 2024. The Audit Committee had reviewed the audit fee proposal provided by RSM and considered that the proposed audit fee might not be appropriate considering the current operation scale of the Group and the prevailing market rates from other professional accounting firms of a similar scale. RSM had confirmed in its resignation letter to the Company and the Audit Committee that there were no matters in respect of its resignation that needed to be brought to the attention of the holders of securities of the Company.

The Board, with the recommendation of the Audit Committee, had resolved to appoint Baker Tilly Hong Kong Limited ("**Baker Tilly**") with effect from 16 July 2024 as the new Auditor to fill the casual vacancy following the resignation of RSM, and to hold office until the next annual general meeting of the Company. The ordinary resolution to re-appoint Baker Tilly as the Auditor had been passed by the Shareholders at the annual general meetings of the Company held on 19 June 2025 and 29 May 2026 respectively.

PURCHASE, SALE AND REDEMPTION OF LISTED SECURITIES

During the six months ended 30 June 2026, neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the Company's listed securities (including Treasury Shares, if any).

As at 30 June 2026, the Company did not hold any Treasury Shares whether in the Central Clearing and Settlement System or otherwise.

PUBLICATION ON WEBSITES

This announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.regentpac.com).

DESPATCH OF INTERIM REPORT

The 2026 Interim Report containing full details of the Company's unaudited consolidated interim results for the six months ended 30 June 2026 will be available on the websites of the Stock Exchange and the Company and be despatched to the Shareholders by the end of September 2026.

By Order of the Board
Regent Pacific Group Limited
James Mellon
Chairman

Hong Kong, 25 August 2026

As at the date of this announcement, the Board comprises six Directors:

Executive Director:
Jamie Gibson *(Chief Executive Officer)*

Non-Executive Directors:
James Mellon *(Chairman)*
Jayne Sutcliffe

Independent Non-Executive Directors:
Mark Searle
Adrian Chan
Ihsan Al Chalabi

DEFINITIONS

In this interim results announcement, the following expressions shall have the following meanings unless the context indicates otherwise:

2025 Annual Report	the Company's annual report for the year ended 31 December 2025
2026 Interim Report	the Company's interim report for the six months ended 30 June 2026
AI	artificial intelligence
Audit Committee	audit committee of the Company
Auditor	auditor of the Group
Board or Board of Directors	Board of Directors of the Company
CEO	Chief Executive Officer of the Company
CG Code	Corporate Governance Code as set out in Appendix C1 of the Listing Rules
Company	Regent Pacific Group Limited, a company incorporated in the Cayman Islands with limited liability, the shares of which are listed on the Main Board of the Stock Exchange and are also traded on the Open Market (Freiverkehr) of the Frankfurt Stock Exchange
Deep Longevity	Deep Longevity, Inc, a wholly owned subsidiary of the Company, and its subsidiary
Director(s)	director(s) of the Company
ED	Executive Director of the Company

EUR or €	Euro, the lawful currency in the Eurozone and other nations and territories
FAFVPL	financial assets at fair value through profit or loss
FDA	The Food and Drug Administration of the US
Fosun Wanbang	復星萬邦(江蘇)醫藥集團有限公司 (Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd.) (formerly known as 江蘇萬邦生化醫藥集團有限責任公司 (Jiangsu Fosun Wanbang Biopharmaceutical Group Co., Ltd.)), a subsidiary of 上海復星醫藥(集團)股份有限公司 (Shanghai Fosun Pharmaceutical (Group) Co., Ltd.)
G&A	general and administrative
Galloway	Galloway Limited, a private limited liability company which is indirectly wholly owned by James Mellon, a substantial Shareholder who is also a NED and Chairman of the Board
GBP or £	Great British pounds, the lawful currency in the United Kingdom
Group	the Company and its subsidiaries
HK$	Hong Kong dollars, the lawful currency in Hong Kong
Hong Kong	The Hong Kong Special Administrative Region of the PRC
INED(s)	Independent Non-Executive Director(s) of the Company
IP	intellectual property(ies)

Listing Rules	Rules Governing the Listing of Securities on the Stock Exchange
Model Code	Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 of the Listing Rules
NDA	New Drug Application
NED(s)	Non-Executive Director(s) of the Company
NMPA	the National Medical Products Administration
Nomination Committee	nomination committee of the Company
Plethora	Plethora Solutions Holdings plc, a wholly owned subsidiary of the Company
PRC or China	The People's Republic of China
R&D	research and development
Recordati	Recordati S.p.A
Remuneration Committee	remuneration committee of the Company
ROU assets	right-of-use assets
Securities Dealing Code	the code governing securities transactions by Directors and relevant employees of the Group, which was adopted on no less exacting terms and required standard set out in the Model Code
Share(s)	ordinary share(s), with voting rights, of US$0.001 each in the capital of the Company
Shareholder(s)	holder(s) of the Share(s)

Stock Exchange	The Stock Exchange of Hong Kong Limited
Treasury Share(s)	has the meaning ascribed to it in the Listing Rules
US	the United States
US$	US dollars, the lawful currency in the US